Related references
Note: Only part of the references are listed.Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
Bin Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Broad Spectrum β-Lactamase Inhibition by a Thioether Substituted Bicyclic Boronate
Anete Parkova et al.
ACS INFECTIOUS DISEASES (2020)
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
Xiaojuan Wang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition
Catherine L. Tooke et al.
RSC MEDICINAL CHEMISTRY (2020)
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2019)
Studies on the inhibition of AmpC and other β-lactamases by cyclic boronates
Samuel T. Cahill et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2019)
Will morphing boron-based inhibitors beat the β-lactamases?
Alen Krajnc et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
Alen Krajnc et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Jodie C. Hamrick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae
Sarah Christina Jane Jorgensen et al.
PHARMACOTHERAPY (2018)
Past and Present Perspectives on β-Lactamases
Karen Bush
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
1401. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects
Brooke Geibel et al.
Open Forum Infectious Diseases (2018)
Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates
Karina Calvopina et al.
MOLECULAR MICROBIOLOGY (2017)
Cyclic Boronates Inhibit All Classes of β-Lactamases
Samuel T. Cahill et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Interaction of Avibactam with Class B Metallo-β-Lactamases
Martine I. Abboud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
David Yuxin Wang et al.
FUTURE MEDICINAL CHEMISTRY (2016)
Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates
Juergen Brem et al.
NATURE COMMUNICATIONS (2016)
Are the physicochemical properties of antibacterial compounds really different from other drugs?
Jean-Paul Ebejer et al.
JOURNAL OF CHEMINFORMATICS (2016)
Escherichia coli: an old friend with new tidings
J. Vila et al.
FEMS MICROBIOLOGY REVIEWS (2016)
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance
S. D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Timothy A. Blizzard et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe
Ann Versporten et al.
LANCET INFECTIOUS DISEASES (2014)
Emergence of Escherichia coli producing extended-spectrum AmpC β-lactamases (ESAC) in animals
Marisa Haenni et al.
FRONTIERS IN MICROBIOLOGY (2014)
Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
Sushmita D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Assay Platform for Clinically Relevant Metallo-β-lactamases
Sander S. van Berkel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis
Robert A. Copeland et al.
ANALYTICAL BIOCHEMISTRY (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Observations on the Deprotection of Pinanediol and Pinacol Boronate Esters via Fluorinated Intermediates
Steven R. Inglis et al.
JOURNAL OF ORGANIC CHEMISTRY (2010)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
PHENIX:: building new software for automated crystallographic structure determination
PD Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2002)
Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase:: Implications for resistance mutations and inhibitor design
RA Powers et al.
BIOCHEMISTRY (2001)
Share Paper
